Skip to content

Author

G. Kroemer

We have 10 of 212 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cell death: immunogenic potential of cuproptosis in cancer

Recent data published in Cell demonstrate that a Cu 2+ -dependent form of regulated cell death (RCD) commonly known as cuproptosis is immunogenic, resulting in the emission of damage-associated molecular patterns (DAMPs) by malignant cells and the initiation of an adaptive anticancer immune response that not only ampli...

Lorenzo Galluzzi, O. Kepp, G. Kroemer · 0 citations
Open access Oct 2026

Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes

ABSTRACT In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues f...

Anne-Laure Mallard de La Varende, M. Fidelle, G. Kroemer et al. · 0 citations
Review Open access Oct 2026

Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications.

The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunothera...

Serena Porcari, L. Bolte, J. Björk et al. · 0 citations
Review Open access Oct 2026

Metabolic hallmarks of regulated cell death

Regulated cell death (RCD) is characterized by distinct molecular execution mechanisms, but its initiation, progression, and biological consequences are increasingly recognized as being shaped by cellular metabolism. Bioenergetic state, redox homeostasis, nutrient availability, metal ion metabolism, inflammatory metabo...

Rui Kang, Xin Chen, G. Kroemer et al. · 0 citations
Review Oct 2026

A context-dependent framework for targeting NAD metabolism in cancer.

Nicotinamide adenine dinucleotide (NAD) occupies a privileged position at the intersection of cellular bioenergetics, redox homeostasis, and signal transduction. Beyond its canonical role in ATP synthesis, NAD serves as an obligate cofactor for enzymes including poly(ADP-ribose) polymerases (PARPs), sirtuins, and CD38,...

Leire Arrizabalaga, Laura Santambrogio, G. Kroemer et al. · 0 citations
Open access Sep 2026

First round of lung cancer screening among patients with atheromatous cardiovascular disease exposed to tobacco: a prospective cohort study.

INTRODUCTION Identification of populations eligible for lung cancer screening (LCS) is a priority question in this field. The primary objective of this study was to quantify lung cancer prevalence after a first round of LCS among patients with history of atheromatous cardiovascular disease (aCVD) and tobacco exposure....

Elsa Armand, C. Buton, Caroline Caramella et al. · 0 citations
Open access Oct 2026

Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.

Autophagy dysfunction and senescence are established drivers of aging, but their potential interaction remains poorly understood. Here we show that age-related decline of chaperone-mediated autophagy (CMA), a pathway for selective lysosomal protein degradation, changes senescent cell properties and impairs their immune...

Rebecca Sereda, Kristen Lindenau, Antonio Díaz et al. · 1 citation
Open access Sep 2026

Glycometabolic, inflammatory and exocrine plasma proteins predict cancer in individuals with cardiovascular disease

Whether a minimal circulating-protein signature anticipates incident cancer in patients with atheromatous cardiovascular disease exposed to tobacco is asked and estimates are conditional on the cancer frequency of this population, conditional on the cancer frequency of this population.

M. Fidelle, David Boulate, T. Pham et al. · 0 citations
Open access Dec 2026

A novel oncolytic peptide synergizing with immunotherapy.

In a recent paper published in Nature, Yuan et al. described an acid-responsive membranolytic peptide that temporally separates lysosomes from later plasma membrane rupture, thereby converting oncolysis into immunogenic cell death. This elegant design permits systemic administration, elicits antigen-specific immunity,...

G. Kroemer, Xiao-Lian Deng, B. Sveinbjørnsson et al. · 0 citations
Open access Sep 2026

STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma

It is reported that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death, yet in vivo validation remains necessary before this strategy can be considered immunogenic.

O. Kepp, G. Kroemer · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.